Comparison of tumour segmentation methods for dosimetry in [Lu]Lu-PSMA I&T treated patients with metastatic castration resistant prostate cancer.

EJNMMI Phys

Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, Aarhus N, 8200, Denmark.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Tumour dosimetry after radionuclide therapy using Lu-labelled radiopharmaceuticals requires determination of the Lu mean concentration, but this is challenging as tumours are often small, or Lu activity is present in nearby organs or other tumours. Here we present a comparison of methods for determination of Lu mean concentration, and in turn absorbed tumour dose, applied to a small number of patients with prostate cancer treated by [Lu]Lu-PSMA I&T. For application of each method, specific criteria on tumour diameter and tumour-background ratio must be fulfilled.

Results: Eighteen tumours in 9 patients were analyzed. Several methods, the so-called Small Volume of Interest (VOI) with a 20 mm diameter sphere, Large VOI and Isocontour methods, were found to be in good agreement. Relative to the chosen reference method (Isocontour method with partial volume correction), the relative percentage differences of Lu concentration using either of these methods were in the range (-23)-26%. The relative differences of absorbed doses were in the range (-16)-19%.

Conclusions: The agreement between the methods permits a comparison between dosimetry studies, where some of these methods are applied. As the application criteria are complementary, it is possible to include both small (> 15 mm diameter) solitary tumours and larger (> 30 mm diameter), possibly non-solitary, tumours in a dosimetry study.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214225PMC
http://dx.doi.org/10.1186/s40658-025-00772-1DOI Listing

Publication Analysis

Top Keywords

[lu]lu-psma i&t
8
prostate cancer
8
determination concentration
8
methods
7
tumours
5
comparison tumour
4
tumour segmentation
4
segmentation methods
4
dosimetry
4
methods dosimetry
4

Similar Publications

Predictive value of metastatic distribution patterns on [Ga]Ga-PSMA PET/CT for [Lu]Lu-PSMA therapy.

Rev Esp Med Nucl Imagen Mol (Engl Ed)

September 2025

Department of Biostatistics, Gaziantep University, Gaziantep, Turkey.

Objective: This study aimed to assess the predictive value of metastatic distribution patterns on Ga-PSMA-11 PET/CT in patients with chemotherapy- and castration-resistant prostate cancer undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.

Materials And Methods: A retrospective analysis was conducted on 48 patients who received ¹⁷⁷Lu-PSMA-617 therapy between April 2019 and August 2023. Demographic, clinical, and laboratory data, along with pre- and post-treatment Ga-PSMA-11 PET/CT images, were evaluated for associations with molecular response and progression.

View Article and Find Full Text PDF

Background And Objective: Large clinical trials, including VISION, have established the safety of combining [Lu]Lu-PSMA-617 with an androgen receptor pathway inhibitor (ARPI). Most patients receiving [Lu]Lu-PSMA-617 in the real-world setting have already progressed on an ARPI. This study aimed to assess the efficacy of [Lu]Lu-PSMA-617 in patients with and without the concurrent use of an ARPI.

View Article and Find Full Text PDF

 [ Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying high-risk patients is crucial. We evaluated pretherapeutic PSMA PET-derived parameters to predict prostate-specific antigen (PSA) response in patients undergoing [ Lu]Lu-PSMA-617 RLT.

View Article and Find Full Text PDF